Insmed | INSM - Des Atouts





Des Atouts Changement Date
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Cytokinetics USD 1.82B 99.77M 2026-09
DBV Technologies USD 215.4M 7.8M 2026-09
Gilead Sciences USD 51.41B 2.05B 2026-09
Heron Therapeutics USD 252.26M 6.05M 2026-06
Insmed USD 2.23B 123.49M 2026-09
Novartis USD 117.15B 1.38B 2026-09
Regeneron Pharmaceuticals USD 44.41B 2.67B 2026-09
Sarepta Therapeutics USD 3.17B 22.45M 2026-09
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
Vertex Pharmaceuticals USD 32.74B 5.31B 2026-09